Japanese drugmaker Teijin Pharma and privately-owned Italian pharmaceutical company Menarini have signed an exclusive distributorship agreement for the marketing of febuxostat, a novel drug developed by Teijin for the treatment of hyperuricemia and gout, in Central and South America, the Commonwealth of Independent States (CIS) and Oceania. Financial terms of the accord were not disclosed.
Menarini has been marketing febuxostat as Adenuric in Europe since March 2010 under marketing rights granted by licensee French drugmaker Ipsen, which earned the latter an upfront fee of 132 million euros ($172.4 million at current exchange rates; The Pharma Letter October 20, 2009). Japanese drug major Astellas has rights to the drug in most of Asia and also India.
Gets rights in 26 new markets
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze